Immunotherapy is a treatment that uses specific components of a person's immune system to
fight diseases. This is usually done by stimulating or assisting one's immune system is …

There is an increasing clinical interest in the measure and achievement of minimal residual
disease (MRD) negativity in the bone marrow of Multiple Myeloma (MM) patients, as defined …

Abstract Background The clonoSEQ® Assay (Adaptive Biotechnologies Corporation,
Seattle, USA) identifies and tracks unique disease-associated immunoglobulin (Ig) …

Recommendations are based on a review of the literature using Medline, PubMed, Embase,
Central, Web of Science searches from the beginning of 2013 up to July 2019. The following …

Measurable (or minimal) residual disease (MRD) in multiple myeloma (MM) refers to low
levels of myeloma cells detectable using advanced diagnostics. MRD testing is evolving …

Great progress has been made in improving survival in multiple myeloma (MM) patients over
the last 30 years. New drugs have been introduced and complete responses are frequently …

PURPOSE The outcomes of patients with myeloma from developing countries are often
lacking because of poor record maintenance. Publications from such settings are also …

Chimeric antigen receptor (CAR) T cells have revolutionized treatment of B cell
malignancies. However, enhancing the efficacy of engineered T cells without compromising …

Assessment of minimal residual disease (MRD) is becoming a standard diagnostic tool for
curable hematological malignancies such as chronic and acute myeloid leukemia. Multiple …

Plasma cell dyscrasias are a heterogeneous group of diseases characterized by the
expansion of bone marrow plasma cells. Malignant transformation of plasma cells depends …